Opinion|Videos|July 24, 2024

Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies

Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and address concerns they anticipate with the potential approval of BTKis for MS patients and strategies for mitigating these concerns.

Video content above is prompted by the following questions:

  • There is only one FDA-approved option for primary progressive multiple sclerosis. What emerging therapies are under investigation for this subtype of MS?
    • Discuss the PERSEUS trial, which is evaluating tolebrutinib in primary progressive multiple sclerosis.
  • What are the potential adverse effects of BTKis and how should they be monitored for and managed?
  • What access concerns do you anticipate with the potential approval of BTKis for patients with MS, and how can they be mitigated?
    • Discuss considerations of BTKis in oncology and how these may relate to MS.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo